Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis
- PMID: 9389990
Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis
Abstract
We have studied the physiological and clinical relevance of measurements of serum total and free IGF-I and IGF-binding protein-3 (IGFBP-3) in 57 previously untreated patients with active acromegaly (32 males, 25 females; mean age 47 years) as compared with sex- and age-matched normal healthy controls. Serum total and free IGF-I, but not IGFBP-3, are suitable biochemical parameters for screening for acromegaly. In acromegalics, the mean 24 h serum GH, total IGF-I and IGFBP-3 levels tend to decrease with age. However, in our series of patients, mean 24 h serum GH levels, IGFBP-3, total and free IGF-I do not correlate with disease activity in acromegaly.
Similar articles
-
Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly.J Endocrinol. 1997 Oct;155 Suppl 1:S17-9; discussion S21. J Endocrinol. 1997. PMID: 9389991 Review.
-
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.Clin Endocrinol (Oxf). 2004 Jul;61(1):138-44. doi: 10.1111/j.1365-2265.2004.02064.x. Clin Endocrinol (Oxf). 2004. PMID: 15212656
-
Use of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults.Growth Regul. 1996 Dec;6(4):222-9. Growth Regul. 1996. PMID: 8971551 Clinical Trial.
-
Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.Clin Endocrinol (Oxf). 2004 Jun;60(6):741-9. doi: 10.1111/j.1365-2265.2004.02049.x. Clin Endocrinol (Oxf). 2004. PMID: 15163339
-
Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.Eur J Endocrinol. 2003 Apr;148 Suppl 2:S15-20. doi: 10.1530/eje.0.148s015. Eur J Endocrinol. 2003. PMID: 12670296 Review.
Cited by
-
Utility of free IGF-I measurements.Pituitary. 2007;10(2):181-7. doi: 10.1007/s11102-007-0025-y. Pituitary. 2007. PMID: 17429595 Review.
-
Nanomedicines in the treatment of acromegaly: focus on pegvisomant.Int J Nanomedicine. 2006;1(4):385-98. doi: 10.2147/nano.2006.1.4.385. Int J Nanomedicine. 2006. PMID: 17722273 Free PMC article. Review.
-
Acromegaly: diagnostic challenges and individualized treatment.Expert Rev Endocrinol Metab. 2025 Jan;20(1):63-85. doi: 10.1080/17446651.2024.2448784. Epub 2025 Jan 5. Expert Rev Endocrinol Metab. 2025. PMID: 39757391 Review.
-
Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis?J Endocrinol Invest. 1999 Apr;22(4):313-5. doi: 10.1007/BF03343563. J Endocrinol Invest. 1999. PMID: 10342368 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous